Lobe-specific modulation of B16MET melanoma lung metastases by nephrilin peptide

Desmond D. Mascarenhas¹,², Puja Ravikumar³, Edward P. Amento³

¹Mayflower Organization for Research & Education, Sunnyvale, CA 94085, USA.
²Transporin, Inc., Sunnyvale, CA 94085, USA.
³Molecular Medicine Research Institute, Sunnyvale, CA 94085, USA.

Correspondence to: Desmond D. Mascarenhas, Ph.D., Mayflower Organization for Research & Education, 428 Oakmead Pkwy, Sunnyvale, CA 94085, USA. E-mail: desmond@transporin.com


Received: 17 May 2020  First Decision: 24 Jun 2020  Revised: 24 Jun 2020  Accepted: 06 Jul 2020  Published: 30 Jul 2020

Academic Editor: Rafat A. Siddiqui  Copy Editor: Cai-Hong Wang  Production Editor: Jing Yu

Abstract

Aim: Nephrilin peptide modulates systemic immune responses to trauma in contexts characterized by simultaneous inflammation and immunosuppression. This study explores the possibility that nephrilin peptide may modulate lung metastasis, which also occurs in an environment of concurrent inflammation and immunosuppression.

Methods: B16MET melanoma cells were injected via the tail vein of mice and the development of lung metastases was recorded in animals treated with nephrilin peptide or vehicle by subcutaneous bolus injection daily for three weeks. In a separate experiment, nephrilin was administered by subcutaneous bolus injection for seven days to study the biodistribution of peptide and possible changes to plasma cytokine levels.

Results: Nephrilin significantly suppressed B16MET lung metastases. Suppression was more effective in deep lobes with the poorest access to circulation: accessory > inferior > middle > superior. In a separate biodistribution study in mice, nephrilin showed similar biodistribution levels in kidney, liver, brain, and left lung, but significantly higher accumulation in the lobes of the right lung in a gradient that matched its effectiveness in suppressing metastases (accessory > inferior > middle). The latter environments were also characterized by significantly higher local concentrations of succinate, a proxy for lower levels of oxygenation.

Conclusion: Nephrilin accumulates preferentially in the deep lobes of the right lung in mice and inhibits B16MET right lung metastases in a lobe-specific manner.
INTRODUCTION
The peptide nephrilin is an inhibitor of Rictor complex derived by fusing a 19 amino acid segment of Protor with the metal-binding domain of human insulin-like growth factor binding protein-3 (IGFBP3)-a 21 amino acid pro-homeostatic sequence that targets and preferentially enters stressed cells\(^\text{[1-2]}\). We have demonstrated the efficacy of nephrilin peptide in combating many of these pleiotropic effects in burn trauma as well as in several rodent models of metabolic and xenobiotic stress\(^\text{[9-14]}\). When nephrilin peptide is injected subcutaneously into rodents, its Protor sequence is believed to reduce oxidative stress in target tissues by modulation of Rac1 phosphorylation and, more speculatively, its IGFBP3 sequence may mediate homeostatic immunomodulatory functions in addition to its described transporter functions\(^\text{[12]}\). Nephrilin treatment following burn injury reverses epigenetic and signaling changes in kidney tissue that lead to the activation of Rac1, and lowers elevations in markers of systemic oxidative stress such as urinary 8-isoprostane and plasma OHDG\(^\text{[10-12]}\). Besides, an analysis of gene expression in the CNS after burn injury showed that nephrilin beneficially modulated the expression of genes associated with astrocytosis, oxidative stress, and immunosuppression\(^\text{[13]}\). Trauma is characterized by the co-existence of pro-inflammatory and immunosuppression phenomena, strikingly reminiscent of what has long been described for metastatic niche formation\(^\text{[15,16]}\). The role of oxidative stress and pro-fibrotic cytokines has been amply documented as instrumental in the sculpting of the latter environment(s). We asked whether nephrilin might modulate the latter environment, as we have shown that it has beneficial effects on the former.

Previous studies have shown that the lobes of the rodent right lung differ in their access to the arterial and lymphatic circulation, susceptibility to anoxia, and local concentrations of pro-inflammatory factors such as lung elastase\(^\text{[17]}\). We were interested in examining the biodistribution and effectiveness of nephrilin peptide in the lobes of the rodent lung, to gain a better understanding of how nephrilin accesses deep lung environments. This variable is relevant in critical care settings, particularly in the context of major comorbidities of sepsis and burn trauma, such as ARDS\(^\text{[18,19]}\). Nephrilin has shown beneficial effects in rodent models of sepsis and burn trauma, as noted above.

Finally, lung metastasis is accelerated by profibrotic and pro-metastatic factors such as CCL12 and TIMP-1\(^\text{[20,21]}\). We examined the possible effects of nephrilin on the circulating levels of these factors.

METHODS
Reagents
Nephrilin peptide (1) and FITC-labelled tracer peptide, the IGFBP3-derived portion of the nephrilin peptide sequence (fitc-KKGFYKKQCRPSKGRKGFCW) were synthesized by Lifetein LLC (Hillborough, NJ). Antibodies for ELISAs were purchased from Abcam (Cambridge, MA), and chemicals from Sigma-Aldrich (St. Louis, MO) unless otherwise specified.

Murine models
Animals were housed in clean cages on a 12 h light/dark cycle with access to standard chow and water \textit{ad libitum}. Animals were allowed to acclimate for one week before the experiment. All animal procedures were performed in adherence to the National Institute of Health's Guide for Care and Use of Laboratory
Animals and approved by the Institutional Animal Care and Use Committee (IACUC) of the Molecular Medicine Research Institute. At the end of the study, period animals were euthanized by decapitation as approved by MMRI IACUC guidelines, the NIH’s Office of Laboratory Animal Welfare (OLAW), and AVMA recommendations.

For the lung metastasis study, 7-week old female B6D2F1 mice (Charles River; 18-22 gram body weight) received implantation via tail vein of 1x10e5 B16MET-e100 tumor cells per animal. Beginning on Day 2, animals received either saline or nephrilin peptide (1.2 mg/kg) daily via subcutaneous bolus injection, for 3 weeks (n = 6 per group). At the end of the treatment period, animals were sacrificed and lung metastases in each lobe of the right lung were counted.

For biodistribution studies, 10-week old male C57BL6 mice (Jackson Laboratories; 30 grams body weight) were used. Animals received either saline or nephrilin peptide (4 mg/kg) + FITC-labelled peptide tracer (1:100 molar ratio to nephrilin) via subcutaneous bolus injection once daily for seven days (n = 3 per group). The concentration of tracer peptide administered is too low to generate measurable biological effects, of itself. At the end of the treatment period, animals were sacrificed and left lung, left kidney, brain (left hemisphere), and liver (left half) were immediately stored in formalin for further histological analysis. Brain (right hemisphere), right kidney, liver (right half), plasma, and each lobe of the right lung were immediately frozen at -80 °C for further analysis.

**Plasma cytokine/chemokine analysis**
Analysis of plasma was performed using a mouse cytokine 44-plex immunoassay (Custom Plex Discovery Assay, Eve Technologies, Calgary, AB). Statistically significant differences (Student’s t-test, P < 0.05) between saline-treated and nephrilin-treated animals in the biodistribution experiment were found in the plasma levels of two of the 44 analytes tested.

**Tissue extracts**
Frozen tissue extracts were prepared using the CellLyticMT extraction buffer (Sigma-Aldrich, St. Louis, MO) as specified by the manufacturer. Extracts were stored at -20 degrees C before assay by ELISA (for nephrilin peptide, using in-house polyclonal antibody #2501) or for succinate assay using a kit purchased from Megazyme, Inc (Chicago, IL).

**Statistical analysis**
Data are presented as means ± SD unless otherwise indicated. Probability values (P values) were computed using Student’s t-test and expressed relative to the saline-treated group.

**RESULTS**

**Biodistribution of nephrilin**
Figure 1 shows tissue sections of the brain, kidney, left lung, and liver from mice injected with either saline or nephrilin (4 mg/kg) + 1:100 FITC-tracer peptide (see methods). A fairly even distribution of peptide across tissues is visible in the slides, and corroborated by the biodistribution of nephrilin peptide in the brain (0.81 μg nephrilin/mg total tissue protein), kidney (0.97) and liver (0.74), as measured by ELISA. The concentration of nephrilin in the left lung was not measured, as that tissue was fixed in formalin. The concentration of nephrilin and tracer peptide in the right lung was measured. Table 1 shows the distribution of nephrilin in the four lobes of the right lung. There is a gradient of accumulation of peptide (μg/mg total tissue protein) in the deep lobes: accessory (5.07) > inferior (3.45) > middle (2.84) > superior (2.12). This gradient is reminiscent of that previously shown for lung elastase in rodent lung[19]. We also measured the concentration of succinic acid in tissue extracts of each lobe of the right lung. Interestingly,
the concentration of succinic acid was 22% higher (P < 0.001) in the accessory, inferior and middle lobes, when compared to the superior lobe, suggesting lower oxygenation levels in those tissues.

**Plasma cytokines**

Of the 44 cytokine/chemokine analytes measured in plasma, only two differed significantly between the mice treated with nephrilin versus those treated with saline: CCL12 (MCP-5) and TIMP-1 were both significantly lower in the nephrilin group [Figure 2]. Both CCL12 and TIMP-1 are believed to play a pro-fibrotic role[^20,21] and fibrosis is canonically described as a feature of the tumor environment[^22].

**Lung metastases**

Table 2 shows B16MET melanoma lung metastases in the saline and nephrilin treated groups on Day 21. The average number of metastases decreases along with the superior > middle > inferior > accessory gradient, consistent with relative access to the circulatory system. However, the percent reduction in

---

[^1]: Tissue nephrilin measured by ELISA (μg nephrilin/mg tissue protein); *P < 0.05 vs. saline-treated group; #P < 0.05 vs. superior lobe.
metastases in the nephrilin-treated group runs in the reverse direction of that gradient, from a 46% reduction in the accessory lobe to a 3% reduction in the superior lobe. Overall, nephrilin reduces B16MET lung metastases by 22% in all lobes combined ($P = 0.017$).

Figure 3 shows a strong and direct relationship between the accumulation of nephrilin in the various lobes and the reduction in metastases in those tissues ($r^2 = 0.98$).

**DISCUSSION**

Nephrilin’s efficacy in reversing the systemic effects of sepsis and burn trauma$^{[9-11]}$ appears to involve pro-homeostatic modulation of the underlying immune dysfunction. In this study, we measured the distribution of nephrilin peptide across lung tissues after administration via subcutaneous bolus injection. Surprisingly, substantial preference of peptide accumulation was observed in lobes of the lung that are distal to the circulation, an environment in which we also showed a higher accumulation of succinate, a proxy for anoxia$^{[23]}$. In previously published work, a similar gradient was shown for concentrations of lung elastase, fragments of which have been implicated in the inflammatory response within these tissues$^{[17]}$.

Nephrilin is effective at reducing B16MET metastases to the lung in this murine model. The effectiveness of the peptide is directly proportional to the peptide’s preferential accumulation in tissues of the deep lung. The potential clinical significance of this pattern of accumulation should be mentioned here: tissues of the deep lung have been associated with morbidity and mortality of respiratory distress syndromes and pneumonia, often comorbid with kidney dysfunction or sepsis, accounting for much of the deadliest burden in ICUs$^{[24,25]}$. Furthermore, these deep tissues are associated with lower oxygen tensions, a feature associated with metastatic niche$^{[26]}$. 

---

**Table 2. B16MET melanoma metastases in lung lobes at 3 weeks post-injection**$^{[2]}$

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Superior</th>
<th>Middle</th>
<th>Inferior</th>
<th>Accessory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline-treated</td>
<td>17.83 ± 3.43</td>
<td>15.83 ± 3.43</td>
<td>14.83 ± 2.64</td>
<td>6.17 ± 1.72</td>
</tr>
<tr>
<td>Nephrilin-treated</td>
<td>17.33 ± 3.33</td>
<td>11.83 ± 2.56*</td>
<td>10.00 ± 4.29*</td>
<td>3.33 ± 1.63*</td>
</tr>
</tbody>
</table>

$^{[2]}$All lobes combined: saline gp 54.67 ± 7.09, nephrilin gp 42.50 ± 7.66, $P = 0.017$; *$P < 0.05$ vs. saline-treated group
Our observation that nephrilin treated animals have significantly lower plasma levels of the pro-fibrotic factors CCL12 and TIMP-1 is particularly intriguing. Fibrosis and metastasis have been linked in previous studies [22]. Whether animals marked at the genetic loci for CCL12 and TIMP-1 might show lowered altered levels of susceptibility to the metastatic spread of melanoma is worthy of exploration.

In the context of metastatic melanoma, the ability to address the formation of a metastatic niche in the deep lung is an intriguing subject for future study. But our results also raise other questions: Can the unusual lung tissue targeting seen with nephrilin peptide in this study presage its use as a vehicle for deep-lung targeted treatments in general? Given the known efficacy of nephrilin peptides in models relevant to other aspects of critical care such as sepsis, burn trauma, and kidney function, the potential usefulness of this peptide for targeting treatments in ARDS is intriguing.

**DECLARATIONS**

**Authors’ contributions**

Contributed to experimental work, experimental design and data discussion: Mascarenhas DD, Ravikumar P

Contributed to funding the research, discussing the data and manuscript writing: Mascarenhas DD, Amento EP

**Availability of data and materials**

For additional data requests, please contact the corresponding author.

**Financial support and sponsorship**

General funds from all participating institutions contributed to the funding of this study.

**Conflicts of interest**

All authors declared that there are no conflicts of interest.

**Ethical approval and consent to participate**

All animal procedures were performed in adherence to the National Institute of Health's Guide for Care and
Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee (IACUC) of the Molecular Medicine Research Institute.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCE